Organ Preservation Market: Global Industry Analysis and Forecast (2024-2030) by Type, Technique and Application

Organ Preservation Market Overview

The term "organ preservation" describes the procedures and methods employed, usually during organ transplantation, to preserve the viability and functionality of organs outside the body. Ensuring the organs are in perfect condition before transplanting them to a recipient is an essential part of the organ transplantation process. The quality of donor organs has been improved by the development of numerous preservation methods and treatments, which have a direct effect on post-transplant morbidity and survival. The Organ Preservation consists of 2 key methods, which include Hypothermic Storage and Sub-zero Organ Preservation. Organ preservation is essential for prolonging the ischemia period of vital organs such as the liver, pancreas, and kidneys, which enables effective organ transplantation and better patient outcomes.

 

The Organ Preservation Market has seen a substantial increase with a projected CAGR of 6.6% for the projected year 2030. Several factors influence the Organ Preservation Market such as constant Technological advances, increasing organ transplantation procedures, Rising healthcare investment, and a growing geriatric population. The market is adversely affected by some major restraining factors which include the shortage of some organs, rejection of organs, high costs associated with organ transplantation and preservation, and limited access to care. The Organ Preservation Market is segmented By Type, Technique, and Application.

 

The Organ Preservation Market is segmented through regions in North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The North American region holds approximately 42.59% of the total market revenue being the most dominant region in the Organ Preservation market as of 2023.  This dominance is attributed to factors like an increase in the number of cases of end-stage renal disease (ESRD) and the consequent growth in kidney transplants, which ultimately fuels the demand for organ preservation solutions.  North American region is followed by Europe holding the second-largest share globally. Whereas, Asia-Pacific is projected to grow at the quickest CAGR in the projected period.

 

Some of the key players dominating the Organ Preservation Market are- 21st Century Medicine Inc., Dr. Franz Köhler Chemie GmbH, Essential Pharmaceuticals LLC, IGL GmbH, Lifeline Scientific Inc., Organ Recovery Systems Inc., Preservation Solutions Inc., XVIVO Perfusion AB, Bridge to Life Ltd., Paragonix Technologies Inc., TransMedics Inc., Waters Medical Systems LLC, BioLife Solutions Inc., Bristol-Myers Squibb Company, CryoLife Inc., Hemarina SA, BioTime Inc., Lifor SA, TissueGene Inc., ToleroTech Inc.

 

Organ Preservation Market Dynamics

Technological Advancements-

Technological advances play a key role in helping the Organic Preservation Market to grow due to the recent developments in technologies such as Perfusion Systems for solid organ preservation, improving the viability of organs like heart, liver, kidneys, and Vascularized composite allograft (VCA). Organ Preservation Technology is experiencing substantial growth in the US and Canadian markets with a projected increase of CAGR 6.6% for the forecasting period. Also with the introduction of technologies like normothermic, hypothermic machine perfusion, and static cold storage (SCS), the market has grown significantly.

 

Increasing Organ Transplantation Procedures- One of the main factors fuelling the organ preservation market is the rise in organ transplant operations. This is because the need for organ preservation solutions is being driven by an increase in end-stage renal disease (ESRD) cases and kidney transplants. End-stage renal Disease (ESRD) in the United States between 2001 and 2020 shows a significant rise in the prevalence of ESRD. The number of ESRD patients increased from 97,856 in 2001 to 134,837 in 2020 which is an increase of 37.8%.  The market for organ preservation was dominated by the organ transplant centers segment. The primary element boosting the acceptability of this end-user is the growing number of transplant centers worldwide.

Rising Healthcare Investment- Significant research and development efforts in the field of organ preservation are facilitated by increased investments in healthcare. This funding encourages the investigation of novel methods that improve the efficacy of preservation measures. For Instance, the US Department of Agriculture funded 500 million USD through a new program in the year 2022 aiming to support innovative projects in organ preservation and biotechnology. The National Institutes of Health (NIH) invested 17.2 USD billion for research on all vaccine technologies before 2020. Upgrades to the infrastructure supporting healthcare, especially organ transplant centers, are being funded. By facilitating effective organ preservation procedures, this infrastructural development hopes to provide ideal circumstances for organ storage and transplantation. Investments have bolstered joint efforts between public and private institutions, creating a favorable atmosphere for organ preservation developments. These collaborations are essential for advancing research and development initiatives.

 

Organ Shortage- Due to the limited supply of organs available for transplantation, organ shortage is a major factor impeding the growth of the organ preservation industry. For instance, in the United States, as of January 2022, over 106,588 patients were waiting for organ transplants, however by the end of 2021, just 41,354 operations had been carried out. There is an increasing need for efficient organ preservation methods and solutions as a result of this disparity between the amount of organs donated and the amount of organs needed. Poor legislative measures, a higher danger of organ trafficking, and a lack of awareness about organ donation are the main causes of the low number of organs donated each year. To solve these problems, the governments of several nations are enacting new legislation; nevertheless, the process is sluggish, and the shortage continues.  

 

Organ Rejection- Organ rejection is a significant challenge that proves to be a key restraining factor for the Organ Preservation market. Organ rejection occurs when the recipient's immune system attacks the transplanted organ, leading to organ failure and the need for transplantation or other treatments. This issue contributes to the limited success rate of organ transplantation, which in turn affects the demand for effective organ preservation techniques and solutions. The goal of organ preservation procedures is to keep organs functional and viable outside of the body, which is essential for a successful transplant. Nonetheless, patients and healthcare professionals continue to have serious concerns about the possibility of organ rejection. Immune Response Challenges, Allograft Rejection, Chronic Rejection, Hyperacute rejection, and Secondary rejection are some of the major cases found in the Organ Rejection phenomena.

 

Organ Preservation Market Segmentation

By type, the Organ Preservation market is further divided into Kidney, Heart, Lung, Liver, and Pancreas. The Kidney segment holds the highest market share in 2023 with a projected CAGR of 7%. The kidney is followed by the Liver for the second highest market share in the Organ Preservation Market. Though the lungs and heart segment are a key contributor to the Organ Preservation Market their market shares are smaller than Kidneys and livers.

 

By Technique, is divided into Static Cold Storage, Hypothermic Machine Perfusion, and Normothermic Machine Perfusion. Static Cold storage is a conventional method that involves the cold storage of organs in a refrigerated, static environment. SCS is primarily used for the preservation of kidney, liver, and pancreas preservation.  Hypothermic Machine Perfusion (HMP) is a technique where perfusing the organ with a cold solution is done and the circulation is done through a machine. The technique provides dynamic preservation which reduces ischemic injury and improves organ efficiency. Whereas, Normothermic Machine Perfusion (NMP) is a technique that provides perfusion at near body temperature, which induces physiological conditions. It comes with certain advantages that mimic natural organ function, which decreases the ischemic damage and potentially increases the preservation time.

 

By Application, the segment is further divided into pharmaceuticals, Organ transplantation, Speciality Centres, and Hospitals. Pharmaceuticals use the preservation of organs for studying drugs, toxicity testing, and other pharma research. Whereas, in Organ Transplantation preservation helps the quality and viability of organs in the transplant process. Hospitals use organ transplants and other medical interventions that are required as they grow their medical capabilities which provides enhanced services and treatments.

Competitive Landscape of Organ Preservation Market

The market for organ preservation is very competitive, with multiple major companies in the market. Which includes 21st Century Medicine Inc., Dr. Franz Köhler Chemie GmbH, Essential Pharmaceuticals LLC, IGL GmbH, Lifeline Scientific Inc., Organ Recovery Systems Inc., Preservation Solutions Inc., XVIVO Perfusion AB, Bridge to Life Ltd., Paragonix Technologies Inc., TransMedics Inc., Waters Medical Systems LLC, BioLife Solutions Inc., Bristol-Myers Squibb Company, CryoLife Inc., Hemarina SA, BioTime Inc., Lifor SA, TissueGene Inc., ToleroTech Inc. To increase their market share, these businesses are constantly collaborating, merging, and developing new technologies. For instance-

 

In 2020, Dr. Franz Köhler Chemie GmbH (Germany) entered into a joint venture with Melchers Group and CICEL (Germany) to establish Köhler in China for the distribution of Custodiol HTK solutions for cardiac and transplant surgery in the Chinese market.

 

OrganOx's Growth Investment: OrganOx, a medical device company, bagged a €29 million growth investment led by Lauxera Capital Partners to advance organ transplantation practices.

 

Paragonix Technologies: Organ preservation company Paragonix Technologies secured $24 million in Series B funding, led by Signet Healthcare Partners.

 

Bridge to Life Ltd- in August 2021, Bridge to Life announced the first close of a $56 million growth financing round led by Perceptive Advisors. The company is also being involved in strategic mergers such as In August 2021 it merged with Tevosol to commercialize a portable normothermic machine preservation technology platform for organ transplantation is one of the company's past mergers.

 

TissueGene Inc- TissueGene Inc., formerly known as Kolon TissueGene, is dedicated to creating gene and cell therapies for osteoarthritis conditions that impact joints such as the hips, spine, and knees. There isn't much information available right now regarding investments, however, on May 15, 2023, Kolon TissueGene closed a deal with a single investor providing 30 million Korean Won in cash.

Organ Preservation Market Scope
Market Size in 2023	USD 260 Mn
Market Size in 2030	USD 406 Mn
CAGR (2024-2030)	6.6%
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Segment Scope	By Type   Kidney Heart Lung Liver Pancreas
	By Technique Static Cold Storage Hypothermic Machine Perfusion Normothermic Machine Perfusion
	By Application Pharmaceuticals Organ Transplantation Speciality Centres Hospitals Others
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

 

Organ Preservation Market Key Players

• 21st Century Medicine Inc.
• Dr. Franz Köhler Chemie GmbH
• Essential Pharmaceuticals LLC
• IGL GmbH
• Lifeline Scientific Inc.
• Organ Recovery Systems Inc.
• Preservation Solutions Inc.
• XVIVO Perfusion AB
• Bridge to Life Ltd.
• Paragonix Technologies Inc.
• TransMedics Inc.
• Waters Medical Systems LLC
• BioLife Solutions Inc.
• Bristol-Myers Squibb Company
• CryoLife Inc.
• Hemarina SA
• BioTime Inc.
• Lifor SA
• TissueGene Inc.
• ToleroTech Inc